Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis

Abstract

BackgroundBlood eosinophil count has been proposed as a predictor of response to inhaled corticosteroid (ICS) in the prevention of acute exacerbations of COPD. An optimal threshold of blood eosinophil count for prescribing ICS has not been agreed. Doubt has been cast on the role by observational studies. The role of inhaled corticosteroids in this relationship, independent of long-acting bronchodilators, has not been examined.MethodsWe conducted a systematic review of post-hoc analyses of randomised controlled trials (RCTs) and observational studies examining three blood eosinophil thresholds and the independent role of ICS. Included studies were categorised by the form (relative or absolute count) and cut point of eosinophil threshold used. Thresholds assessed were relative eosinophil count of 2%, and absolute counts of 150 cells/μL and 300 cells/μL. Three meta-analyses of the effect of ICS use in post-hoc analyses of RCTs based on these counts were carried out. Initial analysis included all studies of ICS vs. any non-ICS regimen. Further analysis examined the effect of ICS, independent of the effect of long-acting bronchodilators.ResultsSixteen studies examined the association between blood eosinophil count and response of exacerbation risk to ICS, in COPD patients. Eleven studies (25,881 patients) were post-hoc analyses of RCTs. Five studies (109,704 patients) were retrospective observational studies. The independent effect of ICS on the reduction of exacerbation risk was 20% at ≥2% blood eosinophil threshold (RR, 0.80; 95% CI, 0.74–0.85), 35% at ≥150 cells/μL blood eosinophil threshold (RR, 0.65; 0.52–0.79), and 39% at ≥300 cells/μL blood eosinophil threshold (RR, 0.61; 0.44–0.78). No association was found in four out of five observational studies.ConclusionThis is the first systematic review to assess, in post-hoc analyses of RCTs, the independent effect of ICS in reducing the risk of COPD exacerbation across a range of blood eosinophil thresholds. Association between ICS prescription and reduced exacerbation risk at these thresholds was confirmed. The lack of association found in the observational studies questions the relevance of these observations to a “real world” COPD population. To clarify the clinical utility of this biomarker, the association should be tested in prospective effectiveness studies.

“NETs and EETs, a Whole Web of Mess”

“…While the benefit of NETs is to clear pathogens, the unchecked deposition of NETs has been associated with deleterious effects to health [105]. NETs have been related to several acute diseases such as acute respiratory distress syndrome [105], hepatic damage during bloodstream infection [106,107], as well as chronic diseases including cystic fibrosis lung disease [26,[50][51][52] and chronic obstructive pulmonary disease (COPD) [108][109][110][111]. In CF patients, NETs associate, as previously mentioned, with an obstruction of the lung and decrease of lung function [80,112,113].…”

Causal Path of COPD Progression-Associated Genes in Different Biological Samples

“…The mechanisms underlying COPD's pathogenesis are still poorly understood (3), but the spectrum of long-term exposure to different kinds of prolusions, smoking, occupational exposures, and genetic basis are mentioned (4). There is no effective treatment or medication for this systemic multi-organ disease based on systematic reviews (5,6). Having a heavy economic burden, speci cally in developing countries, identifying the basics, and comprehending the disease's progressive nature and interfering elements, provides health strategists with better handling options.…”

Suppressor of Variegation 3-9 Homologue 1 Impairment and Neutrophil-skewed Systemic Inflammation Are Associated with Comorbidities in COPD

“…Eosinophilic COPD, which is de ned using peripheral blood eosinophils as a practical biomarker, is a generally accepted treatable trait that is responsive to inhaled corticosteroids (5). Recent meta-analyses (6) have clearly demonstrated a continuous relationship between ICS prescription and a reduced exacerbation risk at variable thresholds, con rming the biomarker role of blood eosinophils. Nevertheless, anti-IL5 or anti-IL-5 receptor monoclonal antibodies have failed to demonstrate consistent effects on patients with high blood eosinophil counts (7).…”